Q1 Earnings Estimate for Veracyte Issued By Leerink Partnrs

Veracyte, Inc. (NASDAQ:VCYT) – Investment analysts at Leerink Partnrs dropped their Q1 2025 EPS estimates for shares of Veracyte in a report released on Monday, April 21st. Leerink Partnrs analyst P. Souda now forecasts that the biotechnology company will post earnings per share of $0.08 for the quarter, down from their previous estimate of $0.11. The consensus estimate for Veracyte’s current full-year earnings is $0.68 per share. Leerink Partnrs also issued estimates for Veracyte’s Q3 2025 earnings at $0.23 EPS.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings results on Monday, February 24th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.29 by $0.07. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The business had revenue of $118.63 million during the quarter, compared to analyst estimates of $110.73 million. During the same quarter last year, the business posted ($0.39) earnings per share.

A number of other analysts have also commented on VCYT. Guggenheim lowered their price objective on Veracyte from $45.00 to $37.00 and set a “buy” rating for the company in a research report on Wednesday, April 9th. Stephens reiterated an “overweight” rating and set a $45.00 price target on shares of Veracyte in a research report on Wednesday, March 26th. StockNews.com lowered shares of Veracyte from a “buy” rating to a “hold” rating in a report on Wednesday, February 26th. UBS Group lifted their target price on shares of Veracyte from $46.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, February 25th. Finally, Craig Hallum assumed coverage on Veracyte in a research note on Thursday, March 20th. They issued a “buy” rating and a $45.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $42.60.

Veracyte Stock Performance

NASDAQ VCYT opened at $32.23 on Thursday. The stock has a market capitalization of $2.51 billion, a P/E ratio of -214.87 and a beta of 2.03. Veracyte has a 52 week low of $19.16 and a 52 week high of $47.32. The stock has a fifty day moving average of $32.25 and a 200-day moving average of $37.28.

Hedge Funds Weigh In On Veracyte

Several institutional investors and hedge funds have recently modified their holdings of VCYT. Ieq Capital LLC acquired a new stake in Veracyte during the 4th quarter worth approximately $580,000. Barclays PLC increased its position in shares of Veracyte by 138.6% during the third quarter. Barclays PLC now owns 146,402 shares of the biotechnology company’s stock worth $4,983,000 after acquiring an additional 85,033 shares in the last quarter. Jennison Associates LLC raised its holdings in shares of Veracyte by 116.3% during the fourth quarter. Jennison Associates LLC now owns 833,754 shares of the biotechnology company’s stock worth $33,017,000 after acquiring an additional 448,251 shares during the period. KBC Group NV lifted its position in Veracyte by 44.6% in the 4th quarter. KBC Group NV now owns 3,872 shares of the biotechnology company’s stock valued at $153,000 after acquiring an additional 1,195 shares in the last quarter. Finally, Proficio Capital Partners LLC acquired a new position in Veracyte in the 4th quarter worth $1,179,000.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.